

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61B 10/00, G01N 21/35</b>	A1	(11) International Publication Number: <b>WO 97/26827</b> (43) International Publication Date: <b>31 July 1997 (31.07.97)</b>
(21) International Application Number: <b>PCT/US97/01126</b> (22) International Filing Date: <b>24 January 1997 (24.01.97)</b>  (30) Priority Data: 08/592,103 26 January 1996 (26.01.96) US  (71) Applicant: BATTELLE MEMORIAL INSTITUTE [US/US]; Pacific Northwest Division, Intellectual Property Services, 902 Battelle Boulevard, P.O. Box 999, Richland, WA 99352 (US).  (72) Inventors: TOTH, James, J.; 1508 West 16th Avenue, Kennewick, WA 99337 (US). SHARPE, Steven, W.; 3897 Ironton Drive, West Richland, WA 99353 (US). THRALL, Karla, D.; 3804 Alder Lake Court, West Richland, WA 99353 (US).  (74) Agent: ZIMMERMAN, Paul, W.; Battelle Memorial Institute, Pacific Northwest Division, Intellectual Property Services, 902 Battelle Boulevard, P.O. Box 999, Richland, WA 99352 (US).	(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: OPTICAL NON-RADIOACTIVE BREATH ANALYSIS

(57) Abstract

The invention is a method of measuring ammonia in a breath sample with a room temperature, near infrared laser. The invention is particularly useful for indicating the presence and activity of an intra-gastrointestinal *Helicobacter pylori* or other ammonia compound producing metabolism.



***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**OPTICAL NON-RADIOACTIVE BREATH ANALYSIS**

5

**FIELD OF THE INVENTION**

The present invention relates generally to a method for breath analysis using non-radioactive biomarkers that are optically quantified. More specifically, the 10 invention is optical quantification of non-radioactive biomarkers in a rough vacuum with infrared light. In this patent application, the word breath is a vapor that includes both exhaled air from the lungs or perspiration vapor or sweat vapor transpired through the skin.

15

**BACKGROUND OF THE INVENTION**

The diagnosis of pathologies and disease by analysis of exhaled air has been postulated since the time of Hypocrites (*ca.*, 400 BC).<sup>1</sup> It is a well established fact that a number of pathologies are associated with the presence of distinct 20 endogenous volatile species in the breath. For instance, both diabetes mellitus and pancreatitis, when left untreated have been associated with the production of relatively large amounts of ketones (acetone).<sup>2,3</sup> Unusually high levels of acetone are also indicative of dietary imbalance.<sup>4</sup> Then acetone can be readily detected by its characteristic sweet odor in the breath. Methane and hydrogen are indicative of 25 intestinal disorders.<sup>5</sup> Hydrogen peroxide is indicative of impaired pulmonary function.<sup>6</sup> Short alkanes such as pentane and ethane are associated with *in vivo* lipid oxidation.<sup>7</sup> Excessive levels of carbon monoxide may be indicative of a malfunction in heme production/breakdown.<sup>8</sup> Carbonyls such as formaldehyde and acetaldehyde have been seen in tumor bearing mice.<sup>9</sup> The combination of finding 30 several species simultaneously (*i.e.*, acetone, methyl ethyl ketone and *n*-propanol) has been statistically correlated with lung cancer in humans.<sup>10</sup> It is further known that analysis of perspiration can be used for indication of state of health or

presence of a disease (U.S. patent 5,465,713). However, analysis of perspiration is an analysis of the liquid of perspiration.

- In addition to monitoring endogenously produced species, it is also possible to administer an isotopically tagged biomarker and detect one or more of the
- 5 exhaled tagged metabolites. This procedure has been successfully utilized to elucidate metabolic pathways and detect disease. A case in point is the diagnosis of *Helicobacter pylori* infection in humans by exhaled air analysis. *Helicobacter pylori* is known to be the primary cause of chronic gastritis in humans. Although many persons infected with *Helicobacter pylori* do not demonstrate overt
- 10 symptoms, the recent discovery of the *H Pylori* organism and its connection to disease of the upper gastrointestinal tract has resulted in major changes in thinking regarding the origin of gastrointestinal disorders.<sup>11</sup> Two exhaled air tests have been established for the diagnosis of *Helicobacter pylori* and include detection of either <sup>13</sup>CO<sub>2</sub> or <sup>14</sup>CO<sub>2</sub> resulting from the ingestion of tagged [C12, C13]urea.<sup>12,13</sup>
- 15 Generally, exhaled air analysis occurs after preconditioning and/or preconcentrating the exhaled air. This may involve passing the exhaled air over a suitable desiccant, through a cold trap or mixing with an inert diluent to reduce water vapor. The sample may then be preconcentrated by bubbling through an appropriate solvent/indicator or condensed to remove only the "active" species.
- 20 Detection of selected species is subsequently performed using either mass spectroscopy, scintillation spectroscopy, colormetric spectroscopy, gas chromatography and, more recently, gas phase infrared absorption spectroscopy.
- Other methods of detecting *Helicobacter pylori* are based upon measuring the presence of ammonia produced. It has recently been discovered that an
- 25 ammonium electrode can be used to indicate the presence of HP bacteria in gastric tissue. (See Butcher, et al., in Digestion, 1992, volume 53, pages 142 through 148). However, this discovery was of the use of such an electrode on in vitro (cell cultures in a laboratory) and not in vivo (in a living patient). Biopsies were required, and information was obtained only for the condition present at the time
- 30 that the biopsy was obtained. No in patient, continuous, real time, ambulatory

monitoring was indicated, nor was the possibility of combining such measurements, with simultaneous measurement of other related parameters.

- An in vivo method of measuring ammonia is reported in U.S. patent 5,477,854 issued Dec. 26, 1995 to Essen-Moller, Anders. Anders discloses a system and a method for in vivo monitoring intra-gastrointestinal concentrations of ammonium during prolonged periods, as an indicator of the presence and activity of an intragastrointestinal *Helicobacter pylori* and other ammonium producing infections. Ambulatory monitoring is possible with Anders' system. Anders uses an ambulatory digital recorder connected to an ammonium sensitive intragastrointestinal catheter and a reference Ag/AgCl catheter. After a calibration, the ammonium catheter is put into its intragastrointestinal position and the recorder samples, once per second, the values of ammonium concentration continuously measured by the ammonium catheter. After recording, the stored values are uploaded to a computer which analyses the ammonium data.
- 15      Uses of tunable infrared semiconductor lasers for exhaled air analysis have been reported in the literature by a number of researchers.<sup>14-20</sup> Advantages of laser absorption over more conventional techniques such as Fourier transform infrared (FTIR)<sup>21</sup> and non-dispersive<sup>22</sup> spectrscopies include higher sensitivity, greater spectral resolution, faster data acquisition and potentially compact packaging of the apparatus for field deployment. Gas phase infrared absorption spectroscopy has the further advantage of requiring minimal preconditioning and/or preconcentration of the sample prior to analysis. In their paper LASER BASED ANALYSIS OF CARBON ISOTOPE RATIOS, Science, vol. 263, 18 Feb. 1994, DE Murnick and BJ Peer use a CO<sub>2</sub> tunable laser to measure a <sup>13</sup>C tracer. Others have used lasers to measure isotopes of carbon, oxygen, nitrogen, hydrogen, carbon monoxide, nitrogen oxide, diatomic nitrogen and water vapor (U.S. patent 5,394,236). In addition, near infrared, room temperature lasers have been used to detect isotopes of carbon monoxide and carbon dioxide (U.S. patent 5,317,156).

It is recognized that distinguishing between isotopes, especially carbon isotopes is often difficult (Murnick and Peer). Obviously, the in-vivo measurement of ammonia is invasive and uncomfortable to the patient.

5 Background References

1. M. Phillips, "Breath Tests in Medicine", Scientific American, pp. 74-79, July 1992.
2. Ed. A. G. Gilman, L. S. Goodman, T. W. Rall and F. Murad, *The Pharmacological Basis of Therapeutics*, pp. 1495-1500, Macmillian Publishing Co., New York, 1985.
3. V.S. Zemskov, V.V. Khrapach and V.A. Liashenko, "Value of exhaled air acetone level in assessing the impairment of secretory pancreatic function in acute destructive pancreatitis", *Klin-Khir*, Vol. 11, pp. 9-11, 1992.
4. S.K. Kundu, J.A. Bruzek, R. Nair and A.M. Judilla, "Breath acetone analyzer: Diagnostic tool to monitor dietary fat loss", *Clinical Chemistry*, Vol. 39, pp. 87-92, 1993.
5. L. LeMarchand, L.R. Wilkens, P. Harwood and R.V. Cooney, "Use of breath hydrogen and methane as markers of colonic fermentation in epidemiological studies: circadian patterns of excretion", *Env. Health Perspect.*, Vol. 98, pp. 199-202, 1992.
6. W.C. Wilson, J.F. Swetland, J.L. Benumof, P. Laborde and R. Taylor, "General anesthesia and exhaled breath hydrogen peroxide", *Anesthesiology*, Vol. 76, pp. 703-710, 1992.
7. T.H. Risby, W. Maley, R.P. Scott, G.B. Bulkley, M. Kazui, S.S. Sehnert, K.B. Schwarz, J. Potter, E. Mezey, A. S. Klein and others, "Evidence for free radical-mediated lipid peroxidation at reperfusion of human orthotopic liver transplant", *Surgery*, Vol. 115, pp. 94-101, 1994.
8. Ed. J.B. West, *Physiological basis of medical practice*, pp. 393-394, William and Wilkins Pub., Baltimore, 1985.

9. S.E. Ebeler, S. H. Hinrichs, A.J. Clifford and T. Shibamoto, "Analysis of reactive carbonyls in the expired air of transgenic mice", *Analyt. Biochem.*, Vol. 205, pp. 183-186, 1992.
10. S.M. Gordon, J.P. Szidon, B.K. Krotoszynski, R.D. Gibbons and H.J. O'Neill, "Volatile organic compounds in exhaled air from patients with lung cancer", *Clinical Chem.*, Vol. 31, pp. 1278-1282, 1985.
11. T.L. Cover and M.J. Blaser, "*Helicobacter Pylori* and gastroduodenal disease", *Annu. Rev. Med.*, Vol. 43, pp. 135-144, 1992.
12. D.Y. Graham, P.D. Klein, A.R. Opekun and T.W. Boutton, "Effect of age on the frequency of active *C. Pylori* infection diagnosed by the [<sup>13</sup>C]urea breath test in normal subjects and patients with peptic ulcer disease", *J. Infect. Disease.*, Vol. 157, pp. 777-780, 1988.
13. B.J. Marshall and I. Surveyor, "Carbon-14 urea breath test for diagnosis of *C. Pylori* associated gastritis", *Clinical Sciences*, Vol. 29, pp. 11-15, 1988.
14. Y. Higashi, H. Ohohara and Y. Sasaki, "Stable isotope analysis using tunable diode laser spectroscopy and its application to <sup>13</sup>C breath test", *Igaku*, Vol. 4, pp. 8-9, 1994.
15. R.U. Martinelli, R.J. Menna, D.E. Cooper, C.B. Carlisle and H. Riris, "Near-infrared InGaAs/InP distributed-feedback lasers for spectroscopic applications", *Proc. SPIE-Int. Soc. Opt. Eng.*, 2148(Laser diode technology and applications VI), pp. 292-307, 1994.
16. K.L. Moskalenko, A.I. Nadezhinskii and E.V. Stepanov, "Tunable diode laser spectroscopy application for ammonia and methane content measurements in human breath", *Proc. SPIE-Int. Soc. Opt. Eng.*, 2204(11th symposium on high-resolution molecular spectroscopy), pp. 448-452, 1993.
17. K.L. Moskalenko, N.V. Sobolev, I.A. Adamovskay, E.V. Stepanov, A.I. Nadezhinskii and S. McKenna-Lawlor, "Tunable diode laser application for fully automated absolute measurements of CO and CO<sub>2</sub> concentrations in human

- breath", Proc. SPIE-Int. Soc. Opt. Eng., 2205(11th symposium on high-resolution molecular spectroscopy), pp. 440-447, 1993.
18. D.E. Cooper, R.U. Martinelli, C.B. Carlisle, H. Riris, D.B. Bour and R.J. Menna, "Measurement of  $^{12}\text{CO}_2/^{13}\text{CO}_2$  ratios for medical diagnostics with 5 1.6mm distributed-feedback semiconductor diode lasers", Appl. Opt., Vol. 32, pp. 6727-6731, 1993.
19. U. Lachich, S. Rotter, E. Shlomo and U. El-Hanany, "Tunable diode laser based spectroscopic system for ammonia detection in human respiration", Rev. Scien. Instrum., Vol. 58, pp. 923-927, 1987.
- 10 20. T.A.A. Aloabaidi and D.W. Hill, "Helium-neon laser infrared analyzer for alcohol vapor in the breath", J.E., Vol. 8, pp. 30-32, 1975.
21. A. Franzblau, S.P. Steven, L. Burgess, A. Qu, R.M. Schreck and J.B. D'Arcy, "The use of a transportable Fourier transform infrared (FTIR) spectrometer for the direct measurement of solvents in breath and ambient air", 15 Amer. Ind. Hyg. Assoc. J., Vol. 53, pp. 221-227, 1992.
22. B. Conlon and J. Dittmar, "Multiple-component nondispersive infrared gas analyzer", Patent: Criticare Systems, Inc., USA, 1992.

#### SUMMARY OF THE INVENTION

20

The invention is a method of measuring ammonia in a breath sample with a laser. The invention is particularly useful for indicating the presence and activity of an intragastrointestinal *Helicobacter pylori* or other ammonia compound producing infections.

25

It is an object of the present invention to provide a non-invasive, accurate method of indicating the presence and/or activity of ammonia compound producing metabolic activity.

30

The subject matter of the present invention is particularly pointed out and distinctly claimed in the concluding portion of this specification. However, both the organization and method of operation, together with further advantages and

objects thereof, may best be understood by reference to the following description taken in connection with accompanying drawings wherein like reference characters refer to like elements.

## 5

## BRIEF DESCRIPTION OF THE DRAWINGS

- FIG. 1 is a flow chart of a PBPK model.  
FIG. 2 is a schematic of a laser system.  
FIG. 3a is a near infrared spectrum of carbon dioxide and water.  
10 FIG. 3b is a near infrared spectrum of carbon dioxide, water and ammonia.  
FIG. 4 is a near infrared spectrum of  $^{15}\text{NH}_3$  and  $^{14}\text{NH}_3$ .  
FIG. 5 is a near infrared absorbance graph of ammonia from four samples.

## 15

## DESCRIPTION OF THE PREFERRED EMBODIMENT(S)

- The invention is a method of measuring ammonia in a breath sample with a laser. The invention is particularly useful for indicating the presence and activity of an intragastrointestinal *Helicobacter pylori* or other ammonia compound producing metabolism.
- 20 Collection of a breath sample is done differently for exhaled air compared to perspiration vapor. For exhaled air, the exhaled air is collected directly through a small diameter tube. For perspiration vapor, the tube is placed on or near the skin to obtain a sample of the perspiration vapor that is in equilibrium or near equilibrium with the perspiration liquid.
- 25 Analysis of breath for the presence of chemical species indicative of specific diseases or as a means of following metabolic processes may be accomplished by (1) measuring absolute concentrations, (2) measuring altered ratios, or (3) measuring tagged species. In the third method of analysis, the tagged species is a biomarker that is preferably non-radioactive with a small natural abundance. In  
30 the present invention, isotopes of nitrogen and/or hydrogen are preferred as would

be present in an ammonia compound including  $^{15}\text{NH}_3$ ,  $^{14}\text{NH}_3$ ,  $\text{N}^2\text{H}_3$ ,  $\text{NH}_4^+$ ,  $^{15}\text{NH}_4^+$ ,  $^{14}\text{N}^2\text{H}_4^+$  and combinations thereof.

*Helicobacter pylori* bacteria are known to break urea down into CO<sub>2</sub> and NH<sub>3</sub>. Hence, a large change in the amount of ammonia is indicative of the presence of *Helicobacter pylori*. According to the present invention, a laser is used to monitor breath samples for NH<sub>3</sub> before and after an oral dose of urea. The detection of the presence of *Helicobacter pylori* may be improved by tagging the urea with an isotope, preferably a non-radioactive isotope. In that case, the ratio of the tagged ammonia to the untagged ammonia indicates the presence of *Helicobacter pylori*.

A physiologically based pharmacokinetic (PBPK) model was also developed to characterize uptake and tissue retention of urea and ammonia both in the rat and in man. Data were used to develop a PBPK model for urea exposure and ammonia disposition as shown in FIG. 1. Arterial pathways 10 and venous pathways 12 of an ammonia model 14 and a urea model 16 are shown. When a metabolically produced ammonia compound reaches the liver, it can be converted to urea or remain as the ammonia compound for transport throughout the body and elimination via the lung or skin. This metabolic conversion is indicated by the dashed line 18 connecting the two models. The urea is eliminated via the kidneys. It is understood that when metabolically produced ammonia compound reaches the liver, it can also be incorporated into proteins and/or amino acids. In the H. Pylori positive case, urea is converted to its components ammonia and carbon dioxide in the gastrointestinal tract.

A system schematic is shown in FIG. 2. The laser 100 may be any laser, but is preferably a room temperature gallium arsenide near infrared laser. A laser beam 102 is directed through a sample chamber 104 containing a breath sample. A detector 106 produces an electrical signal that is amplified and analyzed. A beam splitter 108 may be used to direct a portion of the laser beam 102 to a reference chamber 110 when comparison to a reference sample is desired.

In operation, a breath sample is continuously pulled through the sample chamber 104 for the duration of the measurement (about 10 seconds). No preconcentration is employed. Pretreatment, when used, consists of passing the breath sample through sodium hydroxide pellets to remove water and carbon dioxide. However, ammonia compounds spectra are distinguishable from carbon dioxide and water spectra. Pressure in the sample chamber 104 is preferably kept at less than about 50 Torr, more preferably less than about 30 Torr and most preferably about 20 Torr and regulated by throttling both the pump and inlet. The reduced pressure eliminates pressure broadening of the absorption features. As the sample is pulled through the sample chamber 104, repeated laser scans (1000 scans/sec) are acquired via a 12-bit 1.25 MHz transient digitizer.

The resulting digital data is co-added by a micro-computer (not shown). Each laser scan starts at the same initial spectral frequency, lasts approximately 0.82 ms (i.e., 1024 points x 800 ns) and covers a spectral region of approximately 15 7500 MHz. In this manner, approximately 10,000 scans may be averaged in about 10 seconds. The initial spectral frequency will depend on the absorber (ammonia compound) of interest.

In the sample chamber 104, it is preferred to have both a long optical path length and a reduced operating pressure obtainable by using a modified Herriott 20 cell.<sup>22</sup> This sample chamber 104 has two concave, slightly astigmatic mirrors that are separated by a gap of about 550-mm. One of the mirrors is fastened to a kinematic mount that permits transitional and angular adjustments. The second mirror is fastened to a rigid base plate and the two mirrors are held apart by a rigid aluminum frame. A Pyrex tube surrounds the mirrors so that the mirrors 25 and 3-liter volume between the mirrors can be evacuated and/or filled with a sample. The astigmatic mirrors are configured to allow the output of a laser (preferably a near infrared diode laser) to be reflected between the two mirrors 182 times, for a total optical path length of 100-meters. The astigmatic or modified design of the mirrors reduces fringing effects caused by feedback of the 30 laser that is problematic to any multipass optical system.

- 10 -

The sample chamber 104 may be operated in one of two modes, either as (1) a sample-and-hold or as (2) a constant flow device. In the latter case, an aerodynamic inlet nozzle permits the cell to be operated at a steady-state pressure, when continuously pumped. In either case, the gas pressure in the cell should be  
 5 kept slightly above about 20 Torr (i.e., about 25 Torr) needed to meet Ladenberg's criteria. By adjusting the inlet nozzle cross-section and selecting the appropriate pump size, it is possible to tailor the gas residence time and steady-state pressure in the cell. Equation (12) is general and relates the cell pressure to inlet area and pumping speed as a function of time.

10

$$P_{\text{cell}}(t) = \sqrt{f(1, B)} (P_{\text{in}} Q_{\text{in}} - \exp[A - \sqrt{f(t, B, V)}]) \quad (12)$$

where  $A = \ln(P_{\text{in}} Q_{\text{in}})$ ,  $B = Q_{\text{in}} + Q_p$ ,  $P_{\text{in}}$  is the pressure at the inlet,  $V$  is the volume of the cell and  $Q_{\text{in}}$  and  $Q_p$  are the volume flow rates for the inlet aperture and  
 15 pump, respectively. The volume flow rate is approximated by  $Q_{\text{in}} = C_{\text{in}} \cdot \text{Area(inlet)}$  where,

$$C_{\text{in}} = R(\sqrt{f(g, R, T, M)}) \quad (13)$$

20 and  $g$ ,  $R$  and  $T$  are the conventional thermodynamic constants and  $M$  is the molecular weight of "air" (i.e., 29.2 g/mole). Preferably, the volume flow rate would be matched to the data acquisition rate.

High spectral brightness (0.1 mW) and narrow line widths ( $0.0003 \text{ cm}^{-1}$ ) make tunable lead-salt infrared diode lasers ideal light sources for detection of  
 25 Doppler limited samples. Tunable diode lasers are commercially available and may be specified for operation in the 3 to 300 micron region. A specific tunable diode laser will typically lase  $\pm 50 \text{ cm}^{-1}$  from some specified frequency and may cover a number of different molecular species. In addition, a tunable diode laser may be modulated at high frequencies (e.g., several 100 MHz to 1 GHz) thereby  
 30 permitting use of phase sensitive, ultra-low noise detection schemes. The major

disadvantage of the lead-salt tunable diode laser is the need for cryogenic operation that requires either a mechanical cooler or a small reservoir of liquid or solid cryogenic material.

When the laser 100 is a tunable lead salt diode laser, it is placed inside a 5 temperature stabilized, cooled Dewar unit that maintains the temperature between 120 and 65 K. The entire system can be operated under the control of a micro-computer.

Depending on the spectral region of interest, either high speed indium-antimonide, InSb (3,000 to 1,800 cm<sup>-1</sup>) or mercury-cadmium-telluride, MCT 10 detectors 106 are utilized. A matched preamplifier 112 is used to increase the signal output of the detectors 106 and delivers the signal to both an oscilloscope and transient digitizer (not shown). Both the oscilloscope and digitizer are triggered synchronously with the ramping of the diode laser 100. The oscilloscope trace permits an operator to align and optimize the apparatus in real-time. To increase signal to noise ratio, it is preferred to use a lock-in amplifier 15 114 that admits only signals in phase with the dither 116 frequency.

When a ratio of isotopically tagged species are to be monitored (e.g., <sup>14</sup>NH<sub>3</sub> vs. <sup>15</sup>NH<sub>3</sub>), the criteria for selecting transitions is somewhat different. The two absorption features, corresponding to the two isotopes must occur relatively near 20 to one another ( $D_{n_0} \leq 0.1 \text{ cm}^{-1}$ ). In order to calculate absolute absorbance values and avoid problems associated with changes of laser power vs. frequency, a “zero” waveform is recorded and a “baseline” waveform is generated. The zero waveform consists of acquiring data with the laser 100 turned off. The baseline waveform is associated with the  $I_0$  of the spectral waveform and is created by 25 fitting the data waveform to a polynomial. Points for the polynomial fit are selected so that absorption features are avoided. The zero waveform is first subtracted from the spectral waveform and this difference waveform is then divided by the baseline or  $I_0$  waveform. The resulting waveform,  $I/I_0$  related to transmittance and can be converted directly to absorbance either by taking the 30 natural log or assuming the small number limit of  $\ln[X] = 1-X$ . The individual

peaks are then fit to a Gaussian, Lorentzian or Voigt profile depending on the pressure region.

The theoretical absorbance limit of this apparatus is dictated by shot noise and predicted to be on the order of  $10^{-7}$ . Sensitivity (on a routine basis) is  
5 approximately  $10^{-4}$  absorbance units and limited by the presence of fine fringes traced to 'etaloning within our Herriot cell sample chamber 104. In some cases, we can improve this sensitivity by a factor of 10 with use of optimal filtering which consists of convolving the normalized spectral data with an appropriate response function, determined *a priori*. Absorbance signals corresponding to  
10 hundreds of parts-per-trillion by volume of a specific absorber may then be observed. This is equivalent to a partial pressure of approximately  $10^{-7}$  Torr of absorber in one atmosphere of sample.

Example 1

15 An experiment was performed to demonstrate the utility of the present invention, specifically to demonstrate the ability to distinguish ammonia from carbon dioxide and water. High resolution (75 MHz) spectrometers were used in combination with reduced pressure less than about 30 Torr for sample analysis. The results are shown in FIG. 3a and FIG 3b. FIG. 3a shows spectra for water  
20 30 and carbon dioxide 32. FIG. 3b includes spectra 34, 36 for ammonia. Although one portion of the ammonia spectra 34 is interfered with water spectra 30 the second portion of the ammonia spectra 36 is free of any interference permitting unambiguous detection of ammonia.

25 Example 2

A second experiment was performed to determine the ability to distinguish between ammonia compounds, specifically to distinguish between  $^{14}\text{NH}_3$  and  $^{15}\text{NH}_3$ . Samples containing a separate concentration of each ammonia compound were prepared and analyzed as in Example 1. Results are shown in FIG. 4.

Peaks 40, 42, and 44 are for  $^{14}\text{NH}_3$ . Peaks 46, and 47 are for  $^{15}\text{NH}_3$  . Hence, ammonia compounds are clearly distinguishable.

Example 3

5 A third experiment was performed to ascertain the sensitivity of ammonia compound measurements. A sample of exhaled air, reference sample, perspiration vapor sample, and ambient air sample each containing  $^{15}\text{NH}_3$ , were exposed to a near infrared laser. Results are shown in FIG 5. Sample concentrations are distinguishable from 46 ppb to 150 ppb and quantifiable to 300 ppt.

10

Closure

While a preferred embodiment of the present invention has been shown and described, it will be apparent to those skilled in the art that many changes and modifications may be made without departing from the invention in its broader  
15 aspects. The appended claims are therefore intended to cover all such changes and modifications as fall within the true spirit and scope of the invention.

## CLAIMS

We claim:

- 5        1. A method of indicating the presence of an ammonia compound in a breath sample, the method comprising the steps of:
  - (a) passing the breath sample into a reduced pressure chamber;
  - (b) directing a laser beam through the breath sample; and
  - (c) detecting the intensity of the laser light transmitted through the
- 10      breath sample and obtaining a spectral response and determining a concentration of the ammonia compound in the breath sample.
2. The method as recited in claim 1, wherein a non-radioactive isotope is within a second ammonia compound that is used as a biomarker in the breath sample.
- 15      3. The method as recited in claim 2, wherein the non-radioactive isotope is a nitrogen isotope.
- 20      4. The method as recited in claim 3, wherein the nitrogen isotope is  $^{15}\text{N}$ .
5. The method as recited in claim 1, wherein the reduced pressure is at least 1 Torr.
- 25      6. The method as recited in claim 5, wherein urea is administered to a patient and the breath sample is monitored for the presence of the ammonia compound indicating a breakdown of the urea.
- 30      7. The method as recited in claim 6, wherein the breakdown of urea is caused by *Helicobacter pylori*.

- 15 -

8. The method as recited in claim 1, wherein the breath sample is exhaled air from a lung.

9. The method as recited in claim 1, wherein the breath sample is  
5 perspiration vapor transpired through skin.

10. The method as recited in claim 1, wherein said laser has a wavelength from about 600 nm to about 1700 nm and a lase of about  $\pm 50 \text{ cm}^{-1}$ .

10 11. A method of detecting an infection of *Helicobacter pylori*, comprising the steps of:

- (a) administering urea to a patient,
  - (b) obtaining at least one breath sample from the patient, and
  - (c) measuring an amount of an ammonia compound in said breath
- 15 sample(s).

12. The method as recited in claim 11, wherein step (c) comprises,  
(e) passing said breath sample(s) into a reduced pressure chamber,  
(f) directing a laser beam through the reduced pressure breath  
20 sample(s),  
(g) detecting laser light transmitted through the reduced pressure breath sample(s), and  
(h) obtaining a spectral response of said ammonia compound.

25 13. The method as recited in claim 12, wherein a non-radioactive isotope is within a second ammonia compound and is used as a biomarker in the breath sample.

14. The method as recited in claim 13, wherein the non-radioactive isotope is a nitrogen isotope.

- 16 -

15. The method as recited in claim 14, wherein the nitrogen isotope is  $^{15}\text{N}$ .

16. The method as recited in claim 12, wherein the reduced pressure is at least 1 Torr.

5

17. The method as recited in claim 12, wherein said laser has a wavelength from about 600 nm to about 1700 nm and a lase of about  $\pm 50 \text{ cm}^{-1}$ .

1/4





Fig. 1

2/4



*Fig. 2*

3/4




Fig. 3a




Fig. 3b

4/4




Fig. 4




Fig. 5

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/01126

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61B10/00 G01N21/35

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>REVIEW OF SCIENTIFIC INSTRUMENTS, vol. 58, no. 6, June 1987, NEW YORK US, pages 923-927, XP002031160</p> <p>U. LACHISH ET AL: "Tunable diode laser based spectroscopic system for ammonia detection in human respiration" cited in the application</p> <p>see abstract</p> <p>see page 923, right-hand column, line 3 - line 8</p> <p>see page 926, right-hand column, last paragraph - page 927, left-hand column, line 18; figures 1,6</p> <p>---</p>	1
Y	<p>see page 923, right-hand column, line 3 - line 8</p> <p>see page 926, right-hand column, last paragraph - page 927, left-hand column, line 18; figures 1,6</p> <p>---</p> <p>-/-</p>	2,3,5-8, 10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&\* document member of the same patent family

3

Date of the actual completion of the international search

21 May 1997

Date of mailing of the international search report

06.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Thomas, R.M.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/01126

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 96, no. 4, 30 April 1996 & JP 07 323034 A (HITACHI), 12 December 1995, see abstract	11
Y	---	12-14, 16,17
Y	US 5 394 236 A (MURNICK) 28 February 1995 cited in the application	2,3,5-8, 10, 12-14, 16,17
	see column 1, line 42 - line 49 see column 4, line 65 - column 5, line 23 see column 8, line 37 - line 44 see column 9, line 47 - column 10, line 3 see column 15, line 64 - column 16, line 10; figure 1	
A	---	
A	US 5 317 156 A (COOPER) 31 May 1994 cited in the application	1,5,6,8, 10,12, 16,17
	see column 1, line 6 - line 31 see column 4, line 49 - column 5, line 5 see column 8, line 8 - line 29; figure 2	
A	---	
A	THE LANCET, vol. 345, no. 8955, 15 April 1995, pages 961-962, XP000673516 S. KOLETZKO ET AL: "Isotope-selective non-dispersive infrared spectrometry for detection of Helicobacter pylori infection with <sup>13</sup> C-urea breath test"	
A	---	
A	ZEITSCHRIFT FÜR GASTROENTEROLOGIE, vol. 32, no. 12, December 1994, pages 675-678, XP000672026 B. BRADEN ET AL: "Clinically feasible stable isotope technique at a reasonable price ..."	
A	---	
A	JOURNAL OF CLINICAL GASTROENTEROLOGY, vol. 20, no. S2, 1995, pages s115-s117, XP000672115 H. OHARA ET AL: " <sup>13</sup> C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole"	
	-----	

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 97/01126

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5394236 A	28-02-95	AU 659905 B AU 3211493 A CA 2088100 A EP 0556614 A JP 7020054 A	01-06-95 05-08-93 04-08-93 25-08-93 24-01-95
US 5317156 A	31-05-94	EP 0624245 A JP 7503319 T WO 9315391 A	17-11-94 06-04-95 05-08-93